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Low-serum concentrations of 25-hydroxyvitamin D [25(OH)D] are associated with insulin resistance in adults. Less data are
available in pediatric populations. Serum 25(OH)D serum concentrations were assessed in 125 obese and 31 nonobese children
(age 11.9 ± 2.7y, range 6–16y, 49% male) living in Bonn, Germany. The relationship between 25(OH)D, measured by liquid
chromatography-tandem mass spectrometry, and measures of insulin sensitivity and adipokines adiponectin and resistin were
analyzed. Seventy-six % of subjects were 25(OH)D deﬁcient (<20ng/mL). Higher insulin, homeostasis model assessment-insulin
resistance (HOMA-IR r =− 0.269, P = 0.023), and hemoglobin A1c (HbA1c) as well as lower quantitative insulin-sensitivity
check index (QUICKI r = 0.264, P = 0.030) values were found in obese children with lower 25(OH)D concentrations even after
adjustment for gender, age, and body mass index. Furthermore, 25(OH)D correlated signiﬁcantly with adiponectin, but not with
resistin. Our results suggest that hypovitaminosis D is a risk factor for developing insulin resistance independent of adiposity.
1.Introduction
Obesity is the primary risk factor for the development of
impaired glucose tolerance, type 2 diabetes mellitus, and
the metabolic syndrome. The prevalence of type 2 diabetes
amongchildrenandadolescentshasincreasedatanalarming
rate during the last two decades, with the highest prevalence
among African American adolescents [1].
Studies have shown that lifestyle factors contribute to
this development. As obese children are usually sedentary
and therefore less likely to play outdoors, their exposure to
sunlight may be limited [2]. In addition, unhealthy high
caloric food might be low in mineral and vitamin content
[3, 4]. Both represent risk factors for developing vitamin
D deﬁciency. Additionally, bioavailability of vitamin D in
obese subjects might be low because of its deposition in a
fat tissue [5] and higher body fat mass might be associated
with a higher risk of vitamin D deﬁciency [6]. Vitamin D
plays a central role in skeletal health. Additionally, vitamin D
might also provide protection against major health problems
such as autoimmune disease, cardiometabolic disease, and
cancer [7, 8]. In a recent population study, subjects with
cardiovascular disease had a greater frequency of vitamin
D deﬁciency (deﬁned as 25-hydroxyvitamin D [25(OH)D]
levels <20ng/mL) than those without [9]. Beta-cell function
improves after the administration of vitamin D to ani-
mals [10–12] and humans [13] with vitamin D deﬁciency.
In adult humans, low-serum 25(OH)D levels have been
correlated with impaired glucose tolerance, the metabolic
syndrome, and diabetes, independent of obesity [14–16].
Using the hyperglycemic clamp method, Chiu et al. [17]
found that serum 25(OH)D levels were positively associated
with insulin sensitivity and negatively associated with ﬁrst-
and second-phase insulin secretion. In that study, subjects2 Journal of Obesity
with 25(OH)D deﬁciency (<20ng/mL) had a higher risk of
insulin resistance and metabolic syndrome. In a recent large
population-based health research study, a signiﬁcant inverse
correlation was found between serum 25(OH)D levels and
type 2 diabetes risk as well as subclinical inﬂammation [18].
Although these studies suggest vitamin D deﬁciency as a
risk factor of disturbed glucose homeostasis in humans, it
is still controversial, particularly, in children. Short-term
supplementation studies have provided conﬂicting results
on the eﬀect of vitamin D on glucose tolerance and insulin
sensitivity [13, 17, 19]. And it remains unclear if vitamin
D deﬁciency in children is associated with insulin resistance
and if there is a role for vitamin D replacement in the
treatmentofglucoseintoleranceinthisagegroup.Hormones
such as the adipokines adiponectin and resistin are a possible
link between insulin resistance and adiposity. Adiponectin
exerts anti-inﬂammatory eﬀects, appetite-restraining eﬀects,
and counters insulin resistance, thereby oﬀering protective
mechanismsagainstthedevelopmentofbothT2DMandcar-
diovascular disease. Resistin is involved in insulin sensitivity
and has been shown to modulate both glucose tolerance and
lipid metabolism in vivo and in vitro [20].
To further evaluate whether vitamin D deﬁciency is
associated with insulin resistance and changes of adipokine
secretion, we measured serum 25(OH)D concentrations in
156 children and adolescents (125 obese, 31 nonobese) using
liquid chromatography-tandem mass spectrometry [21]. We
hypothesized that low 25(OH)D levels are associated with
insulin resistance independent of adiposity.
2. Methods
2.1. Patients and Anthropometric Data. Both groups pre-
sentedtoandwereexaminedattheDepartmentofPediatrics,
University of Bonn, and consecutively recruited at the
endocrine and general pediatric outpatient clinics without
any further selection beside the criteria listed below. Pro-
tocols were approved by the institutional review boards at
the University Bonn, Germany, as well as Seattle Children’s
Hospital. Written parental consent and/or patient assent
obtained and investigations were conducted according to
the principles expressed in the Declaration of Helsinki. We
examined anthropometrical markers. Height was measured
to the nearest cm using a rigid stadiometer and weight
was measured in underwear to the nearest 0.1kg using a
calibratedbalancescale.Bodymassindex(BMI)anditsstan-
darddeviationscore(SDS-BMI)werecalculatedasdescribed
previously [22]. Obesity was deﬁned by BMI greater than
the 97th percentile in a national population as described
previously [22]. Pubertal developmental stage was assessed
using the standards of Marshall and Tanner [23, 24]. Inclu-
sion criteria were normal weight or obese male or female
children age 6–16 years old. Exclusion criteria were current
endocrine disorders, calcium metabolism disorders, syndro-
mal obesity, premature adrenarche, diabetes mellitus, or
intake of prescription medications. Thirty-one nonobese
(age 12.2 ± 1.8y, 52% male) and 125 obese (age 11.7 ± 3.0y,
48% male) children were recruited. Twenty-six percent of
all children (27% of obese, 20% of nonobese children) had
a migration background (mostly Turkish or Arab-Islamic
background).
2.2. Laboratory Tests. Insulin was measured by micropar-
ticle-enhanced immunometric assay (Abbott), glucose on
a Vitros analyzer (Ortho Clinical Diagnostics), and HbA1c
using a Variant II analyzer (Biorad). Serum total adiponectin
and resistin were determined by Luminex xMAP technology
(Millipore, Billerica, Man, USA) on a Luminex 200 instru-
ment(LuminexCorp.,Austin,Tex,USA).Theintra-assayCV
was <8% and the inter-assay CV < 14%. Insulin resistance
was estimated from fasting plasma measurements using
the HOMA-IR (Insulin [mU/L] × Glucose [mmol/L]/22.5)
and insulin sensitivity was estimated by QUICKI (1/[log
insulin (mU/L) + log baseline glucose (mg/dL)]) [25]. We
measured 25(OH)D serum levels using HPLC tandem mass
spectrometry [26, 27]. The intra- and interassay CVs were
2.8% and 6.2%, respectively.
2.3. Statistical Analysis. All statistical analyses were per-
formed in Excel (Microsoft), Prism (GraphPad Software),
or SPSS (IBM) and all tests of signiﬁcance were two tailed.
Subjects were divided into quartiles based on their serum
25(OH)D concentrations (Table 1). One-way ANOVA was
used to test for a linear trend across quartiles of plasma
25(OH)Dconcentrationsaswellasforlinearregressionanal-
yses. We also performed multiple linear regression analyses
utilizing plasma 25(OH)D concentrations as a continuous
variable.
3. Results and Discussion
3.1. Results in All Studied Subjects. Mean ± SD 25(OH)D
concentration of all subjects was 15.8 ± 6.6ng/mL and
25(OH)D concentrations were not statistically diﬀerent in
obese children (obese: 16.2 ± 6.8ng/mL; nonobese: 13.6 ±
5.2ng/mL). We found that 25(OH)D concentrations of 96%
of all subjects were below the normal threshold (<30ng/mL)
and 76% of all studied subjects were 25(OH)D deﬁcient
(<20ng/mL). There were signiﬁcant seasonal changes of
25(OH)D concentrations with signiﬁcantly higher concen-
trations from July to October compared to January to April
(P<0.05, Figure 1). In correlation analyses, we found that
25(OH)D levels correlated with HOMA-IR (r =− 0.173,
P = 0.031) and QUICKI (r = 0.157, P = 0.050). As both
measures, HOMA-IR and QUICKI, depend also on the
degree of adiposity, we next set out to determine if there
was an association between 25(OH)D concentrations and
thesemeasuresofglucosehomeostasisafteradjustingforage,
gender, and SDS-BMI and included all obese and nonobese
subjects in this analysis. Even after these adjustments,
25(OH)D correlated signiﬁcantly with HOMA-IR (r =
−0.269, P = 0.023) and QUICKI (r = 0.264, P = 0.030).
3.2. Results in Obese Subjects. O b e s es u b j e c t sw e r ed i v i d e d
into quartiles based on their serum 25(OH)D concentra-
tions. Using one-way ANOVA tests for trend and linear
regression, there were no associations between 25(OH)DJournal of Obesity 3
Table 1: Fasting glucose metabolism parameters in 125 obese children, in quartiles (n = 30–32) of plasma 25-hydroxy vitamin D
concentrations.
Quartiles based on plasma 25-hydroxyvitamin D levels
Test for Trend (P values)
1234
25(OH)D (ng/mL) 8.0 ± 2.31 3 .6 ± 1.21 7 .5 ± 1.22 5 .3 ± 4.3
Age (years) 11.6 ± 3.11 0 .8 ± 3.41 0 .9 ± 3.71 0 .0 ± 3.7 0.114
Gender (% male) 60% 35% 41% 56% 0.879
BMI-SDS 2.7 ± 0.62 .7 ± 0.52 .7 ± 0.62 .7 ± 0.3 0.710
Tanner stage 2.9 ± 1.42 .4 ± 1.42 .6 ± 1.72 .2 ± 1.3 0.107
Glucose (mg/dL) 87.8 ± 8.68 3 .5 ± 11.88 3 .9 ± 11.28 1 .9 ± 11.6 0.050
Insulin (μU/mL) 20.6 ± 16.61 4 .2 ± 13.51 3 .7 ± 7.41 2 .3 ± 9.2 0.010
HOMA-IR 4.4 ±3.42 .9 ± 2.92 .8 ± 1.62 .5 ± 2.2 0.008
QUICKI 0.32 ±0.04 0.34 ±0.06 0.34 ±0.05 0.36 ±0.06 0.003
Hemoglobin A1c (%) 5.37 ± 0.31 5.55 ± 0.42 5.17 ± 0.36 5.21 ± 0.38 0.035
All data are means ± standard deviation except for gender.
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Figure 1: Seasonal changes of 25(OH) serum concentrations in
all studied subjects showing signiﬁcantly higher levels in summer
and early fall (July–October), compared to winter and early spring
(January–April,
∗P < 0.05).
levels and age, gender, or Tanner stage for pubertal devel-
opment (Table 1). In addition, there was no association
between 25(OH)D concentration and SDS-BMI by ANOVA,
but there was a signiﬁcant trend towards higher insulin con-
centrations, insulin resistance HOMA-IR, hemoglobin A1c
values, and lower insulin sensitivity QUICKI in subjects with
lower 25(OH)D concentration (Table 1, Figure 2). In obese
subjects, we also analyzed adiponectin and resistin levels.
Serum adiponectin was signiﬁcantly lower in the lowest
compared to the highest 25(OH)D quartile (Figure 3(a)),
whereas no signiﬁcant diﬀerences between the quartiles
were found for resistin. Serum 25(OH)D concentrations
correlated signiﬁcantly with adiponectin (Figure 3(b)). Even
after adjusting for SDS-BMI, 25(OH)D correlated with
adiponectin (r = 0.192, P = 0.031), but not with resistin
(r =− 0.156, P = 0.078).
3.3. Discussion of Results. To summarize, low 25(OH)D
serum levels were associated with low adiponectin con-
centrations and higher insulin resistance. Ninety-six %
of all studied subjects had suboptimal 25(OH)D levels
(<30ng/mL) and 76% of all studied subjects were vitamin D
deﬁcient (deﬁned as 25(OH)D <20ng/mL), which is higher
than the reported rate from the USA [28] and similar to a
recent study in French-Canadian children and adolescents
[29]. In a recent study investigating vitamin D status in
Norwegian children, 50% of subjects had 25(OH)D levels
below 30ng/mL [30].
These ﬁndings are important as it is becoming increas-
ingly recognized that vitamin D deﬁciency continues to be
largely undertreated in children and adults worldwide [31].
In general, 25(OH)D concentrations below 20ng/mL are
considered to indicate vitamin D deﬁciency, whereas levels
between 20 to 30ng/mL indicate a relative insuﬃciency, and
levels of 30ng/mL or greater indicate suﬃcient vitamin D
[13, 31]. Obese children are more likely to be sedentary
with reduced sunlight exposure [2]. In addition, children
oftenconsumehighcaloricfoodslowinmineralandvitamin
content[3].Theselifestylefactorsincreasetheriskofvitamin
D deﬁciency; furthermore, a higher body fat mass as well
as limited bioavailability of vitamin D caused by trapping
vitamin D in adipose tissue may further increase the risk
of vitamin D deﬁciency among obese children compared
to normal weight, active children [5, 6]. Black American
childrenandadolescentshaveahigherriskforlowvitaminD
status as demonstrated in a recent pediatric study performed
in the USA in which low levels of 25(OH)D were associated
with higher body mass index and fat mass, and lower levels
of HDL [32]. In a large study investigating 25(OH)D levels
in German children and adolescents, higher prevalence of4 Journal of Obesity
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Figure 2: Insulin resistance HOMA-IR (a) and insulin sensitivity
QUICKI (b) concentration in relation to 25(OH)D serum levels in
obese children.
vitamin D deﬁciency was found among immigrants from
Turkey, Arab-Islamic countries, Asia, or Africa [33].
Vitamin D receptors (VDRs) are ubiquitously expressed
in several tissues, including gut, liver, adipose tissues, cardiac
and skeletal muscles, β-cells, and immune cells, such as lym-
phocytes, dentritic cells, and monocytes/macrophages [34].
It has therefore been hypothesized that low-serum vitamin
D status could play a signiﬁcant role in the pathogenesis of
metabolic syndrome [35], type 1 diabetes [36], and T2DM
[13, 15, 37–39]. Vitamin D can also have diverse eﬀects on
the immune system, particularly on the function of mono-
cytes, macrophages, and T cells [7], and it has been observed
to inhibit cytokine production [40]. Adipocytes and adi-
posetissuemacrophagessecreteproinﬂammatorymolecules,
which have been proposed to play a major role in the
development of insulin resistance in obesity [41, 42]. It is
therefore possible that vitamin D deﬁciency contributes
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Figure 3: Serum adiponectin in levels in diﬀerent quartiles (a) for
serum 25(OH)D obese children (Q1: 8.0 ± 2.3; Q2: 13.6 ± 1.2;
Q3:17.5 ± 1.2; Q4:25.3 ± 4.3ng/mL).
∗P < 0.05. Adiponectin
concentration in relation to 25(OH)D serum levels (b) in obese
children.
to insulin resistance and the development of metabolic
syndrome secondary to inﬂammation.
Administration of vitamin D to deﬁcient humans and
animals improves β-cell function [10, 17], whereas low
25(OH)D levels are associated with insulin resistance [5].
Pancreatic β-cell impairment due to vitamin D deﬁciency
would cause increased average glucose concentrations. As a
result, the inverse correlation between vitamin D status and
HbA1c concentrations in our study supports the hypothesis
that vitamin D deﬁciency is associated with poorer glycemic
control which can be caused by β-cell dysfunction as well
as insulin resistance. The relationship between HbA1c andJournal of Obesity 5
25(OH)D concentrations was independent of body mass,
further establishing an independent association between
vitamin D status and glucose homeostasis in obese adoles-
cents. In addition to the eﬀects of vitamin D deﬁciency on β-
cell function, other pathophysiological mechanisms include
unfavorable eﬀects on liver and reduced immunomodula-
tion. In a recent study performed in rats, we demonstrated
that vitamin D deﬁciency can contribute to nonalcoholic
steatohepatitis, insulin resistance, and increased cytokine
secretion [43].
The present study conﬁrms a previous investigation that
alsodemonstratedthat25(OH)Dwasassociatedwithinsulin
sensitivity in obese children [44]. However, lower insulin
sensitivity could also be related to an increased body fat mass
in obesity. Therefore, we adjusted our correlation analyses
to SDS-BMI as a clinical surrogate marker for adiposity. In
the present study, the relationship between 25(OH)D and
measures of insulin sensitivity and resistance persisted even
after adjustment for body mass, which supports the hypoth-
esis that low 25(OH)D may in fact be directly associated with
insulin resistance irrespective of body fat mass.
Recently in a small study of 34 African-American adoles-
cents, low 25(OH)D levels correlated with low adiponectin
levels and obesity [45]. We found a negative correlation
between serum 25(OH)D and adiponectin levels even after
correction for SDS-BMI. As mentioned above, vitamin D
can also have diverse eﬀects on the immune system. The
coexistence of obesity and a low-grade inﬂammatory state
is well described in children, and previous studies showed
that low adiponectin levels are associated with higher
concentrations of inﬂammatory makers in blood [46, 47].
Low adiponectin levels are associated with a higher insulin
resistance, higher levels of c-reactive protein, and lower HDL
levels of in children [46]. Therefore, the higher degree of
insulin resistance and inﬂammation and lower HDL levels in
obesechildrenwithlow-vitamin-Dstatusmightberelatedto
low adiponectin levels.
Resistin was initially identiﬁed as an adipokine released
from adipose tissue and thought to play a role in insulin
resistance [48]. In humans, resistin is secreted by adipocytes
and by macrophages in adipose tissue and liver, likely stim-
ulating the secretion of proinﬂammatory molecules [49, 50].
Some studies showed that serum-resistin levels are elevated
in obesity, however, the role of resistin in insulin resistance
and type 2 diabetes still remains controversial [51, 52]. In
the present study, we did not detect a correlation between
25(OH)D levels and serum resistin in obese children.
In a pediatric population, Reinehr et al. [53] examined
obese children and found a signiﬁcant increase in 25(OH)D
levels after a lifestyle intervention induced weight loss. In
am o r er e c e n ts t u d yi na d u l tw o m e n ,w e i g h tl o s sw a sa l s o
associated with an increase of 25(OH)D levels and was
accompanied by improved insulin resistance [54]. For treat-
ment of vitamin D deﬁciency, it is important to note that the
American Academy of Pediatrics (AAP) recommended that
daily intake of vitamin D of 400IU is insuﬃcient to correct
vitamin D deﬁciency in obese African American children
[2, 55]. New guidelines recommend much higher doses to
treatvitaminD deﬁciencyin childrenandadolescents, which
is in particular important in obese subjects [56].
As a strength of this study, 25(OH)D concentrations
were LC-MS/MS method to some previous studies, where
25(OH)D levels have been quantiﬁed by immunoassays or
competitive protein-binding assays that are known to have
variable cross-reactivity with other vitamin D metabolites
[29, 30, 32, 44, 57, 58]. For that reason, the LC-MS/MS
method is now considered as the gold-standard for vitamin
Dm e a s u r e m e n t s[ 27, 59].
This study has a few limitations. First, BMI percentiles
were used to classify overweight. Although BMI is a good
measure for assessing overweight in children and adolescents
[60], one needs to be aware of its limitation because of its
unreliability as an indicator of fat mass. A high BMI may be
an indication of a high fat mass but it could also be caused
by a larger mass of skeletal muscle, and the relation of BMI
for age to body fatness among children and adolescents also
diﬀersbyrace/ethnicity[61].Second,wecouldstudyvitamin
D status only in relatively fewer nonobese children. Third,
we did not assess parathyroid hormone levels, which were
related to BMI in a previous pediatric study [53]. Fourth,
the interpretation of the data is limited due to the cross-
sectional study design. Future vitamin D treatment studies
are required to investigate the eﬀectiveness of vitamin D
administration in the treatment of the metabolic syndrome
or insulin resistance, in particular to test whether vitamin
D treatment can lead to increased insulin sensitivity and
adiponectin secretion.
4. Conclusion
In conclusion, the prevalence of hypovitaminosis D is high
among obese and nonobese children living in Germany,
and low-serum concentrations of 25(OH)D are associated
with impaired insulin sensitivity and low-adiponectin serum
levels. To investigate the impact of vitamin D treatment in
obese children and the role of vitamin D on glucose home-
ostasis and low-grade inﬂammation, future studies should
use highly sensitive measures of insulin sensitivity and β-cell
serum markers well as adiponectin.
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